{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:35:58Z","timestamp":1792197358817,"version":"4.4.0"},"reference-count":116,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Engineering oncolytic adenoviruses (OAds) to treat renal and bladder cancers has advanced rapidly. Leveraging insights into adenovirus biology, the molecular pathology of cancer, and recent progress in tumor immunology, multiple strategies have been developed to enhance the antitumor specificity and overall efficacy of OAds as anticancer therapeutics. Combination with other cancer treatment modalities has shown synergistic effects, further augmenting their therapeutic potential. In this review, we discuss the most recent advances in oncolytic adenovirus designs that tailor this vector platform for the treatment of renal and bladder cancers. We further summarize findings from preclinical animal studies demonstrating tumor suppression by OAds, as well as results from clinical trials evaluating their safety and efficacy in cancer patients. Collectively, the accumulated data highlights the significant potential of engineered oncolytic adenoviruses as a novel therapeutic modality for cancer patients that have limited treatment options.<\/jats:p>","DOI":"10.3389\/fmicb.2025.1729087","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T05:13:19Z","timestamp":1765257199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Oncolytic adenoviruses in bladder and kidney cancers: emerging strategies and next frontiers"],"prefix":"10.3389","volume":"16","author":[{"given":"Jia","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry M.","family":"Shayakhmetov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.3390\/cancers14235733","article-title":"The underestimated role of the p53 pathway in renal cancer","volume":"14","author":"Amendolare","year":"2022","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"200979","DOI":"10.1016\/j.omton.2025.200979","article-title":"Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma","volume":"33","author":"Arias","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"eabc6659","DOI":"10.1126\/scitranslmed.abc6659","article-title":"Systemic cancer therapy with engineered adenovirus that evades innate immunity","volume":"12","author":"Atasheva","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ymthe.2021.02.001","article-title":"Oncolytic viruses for systemic administration: engineering a whole different animal","volume":"29","author":"Atasheva","year":"2021","journal-title":"Mol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/path.2689","article-title":"VHL and HIF signalling in renal cell carcinogenesis","volume":"221","author":"Baldewijns","year":"2010","journal-title":"J. Pathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/PPO.0b013e3182a102d1","article-title":"PBRM1 and BAP1 as novel targets for renal cell carcinoma","volume":"19","author":"Brugarolas","year":"2013","journal-title":"Cancer J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J. Urol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5800","DOI":"10.1038\/s41467-019-13608-1","article-title":"PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth","volume":"10","author":"Cai","year":"2019","journal-title":"Nat. Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12985-017-0818-1","article-title":"A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression","volume":"14","author":"Cao","year":"2017","journal-title":"Virol. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"10744","DOI":"10.1111\/jcmm.15697","article-title":"Absent in melanoma 2 enhances anti-tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer","volume":"24","author":"Chai","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.3892\/mmr.2014.2987","article-title":"Novel oncolytic adenovirus sensitizes renal cell carcinoma cells to radiotherapy via mitochondrial apoptotic cell death","volume":"11","author":"Chen","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","article-title":"Immune responses to adenovirus and adeno-associated virus in humans","volume":"6","author":"Chirmule","year":"1999","journal-title":"Gene Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.3390\/cancers14194693","article-title":"The emerging role of radiation therapy in renal cell carcinoma","volume":"14","author":"Christensen","year":"2022","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.ymthe.2022.01.034","article-title":"Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens","volume":"30","author":"Coughlan","year":"2022","journal-title":"Mol. Ther."},{"key":"B17","first-page":"6877","article-title":"Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas","volume":"63","author":"Cuevas","year":"2003","journal-title":"Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"189372","DOI":"10.1016\/j.bbcan.2025.189372","article-title":"Unveiling the TGF-\u03b2\/Smad signaling in renal carcinoma progression: prognostic and therapeutic insights","volume":"1880","author":"Dias","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-3-662-05599-1_9","article-title":"Replicating adenoviruses in cancer therapy","volume":"273","author":"Dobbelstein","year":"2004","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1545542","DOI":"10.3389\/fonc.2025.1545542","article-title":"Advances in preclinical and clinical studies of oncolytic virus combination therapy","volume":"15","author":"Du","year":"2025","journal-title":"Front. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2342599","DOI":"10.1080\/15384047.2024.2342599","article-title":"Understanding and overcoming resistance to immunotherapy in genitourinary cancers","volume":"25","author":"Evans","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.virusres.2013.12.021","article-title":"Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells","volume":"181","author":"Fang","year":"2014","journal-title":"Virus Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/15384047.2016.1190485","article-title":"Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell","volume":"17","author":"Fang","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"106701","DOI":"10.1016\/j.phrs.2023.106701","article-title":"Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma","volume":"189","author":"Fang","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2407532","DOI":"10.1080\/2162402X.2024.2407532","article-title":"Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses","volume":"13","author":"Feodoroff","year":"2024","journal-title":"Oncoimmunology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Garcia-Carbonero","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.urolonc.2021.11.014","article-title":"Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States","volume":"195","author":"Geynisman","year":"2022","journal-title":"Urol. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.urology.2012.12.023","volume":"920","author":"Gotoh","year":"2013"},{"key":"B31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3390\/ph18040511","article-title":"Preclinical efficacy and safety of an oncolytic adenovirus KD01 for the treatment of bladder cancer","volume":"18","author":"Guo","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/1535-7163.MCT-07-0176","article-title":"Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses","volume":"6","author":"Guse","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","article-title":"Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s13277-013-0847-3","article-title":"Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3+ T cell","volume":"34","author":"Han","year":"2013","journal-title":"Tumour Biol."},{"key":"B35","article-title":"Treatment strategies for locally advanced and metastatic urothelial carcinoma based on molecular profiles: a review","author":"Hashimoto","year":"2025","journal-title":"Histol. Histopathol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.3390\/ijms21176072","article-title":"Mutational landscape and environmental effects in bladder cancer","volume":"21","author":"Hayashi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3181\/00379727-85-20825","article-title":"Recovery of new agent from patients with acute respiratory illness","volume":"85","author":"Hilleman","year":"1954","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/ijms21031106","article-title":"STAT3\/5 inhibitors suppress proliferation in bladder cancer and enhance oncolytic adenovirus therapy","volume":"21","author":"Hindupur","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1021\/mp200649g","article-title":"Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth","volume":"9","author":"Hsiao","year":"2012","journal-title":"Mol. Pharm."},{"key":"B40","unstructured":"Hua\n              W.\n            \n          \n          Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer [Internet]\n          \n          2022"},{"key":"B41","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/cgt.2010.5","article-title":"Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma","volume":"17","author":"Huang","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.urolonc.2018.10.015","article-title":"Mutational landscape of non-muscle-invasive bladder cancer","volume":"40","author":"Hurst","year":"2022","journal-title":"Urol. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"Kalyuzhniy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5152\/tud.2024.24024","article-title":"Prognostic value of TGF-\u03b2 expression in bladder cancer: a systematic review and meta-analysis","volume":"50","author":"Kianmehr","year":"2024","journal-title":"Urol. Res. Pract."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1382619","DOI":"10.3389\/fimmu.2024.1382619","article-title":"Heterologous Ad26\/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities","volume":"15","author":"Klingler","year":"2024","journal-title":"Front. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s42003-020-0873-9","article-title":"Pan-cancer molecular analysis of the RB tumor suppressor pathway","volume":"3","author":"Knudsen","year":"2020","journal-title":"Commun. Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/0959-437X(93)90126-A","article-title":"Gene therapy: adenovirus vectors","volume":"3","author":"Kozarsky","year":"1993","journal-title":"Curr. Opin. Genet. Dev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1126\/science.adn3528","article-title":"Tumor-killing viruses score rare success in late-stage trial","volume":"382","author":"Leslie","year":"2023","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2024.10.006","article-title":"Preclinical assessment of the efficacy of B7-H3 CAR-T in renal cell carcinoma","volume":"176","author":"Li","year":"","journal-title":"Mol. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"","journal-title":"Nat. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-024-03324-9","article-title":"Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial","volume":"31","author":"Li","year":"2025","journal-title":"Nat. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1089\/hum.2018.026","article-title":"The oncolytic adenovirus XVir-N-31 as a novel therapy in muscle-invasive bladder cancer","volume":"30","author":"Lichtenegger","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Linehan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1111\/j.1349-7006.2012.02380.x","article-title":"Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell","volume":"103","author":"Liu","year":"2012","journal-title":"Cancer Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1604395","DOI":"10.3389\/fimmu.2025.1604395","article-title":"Changing landscape of first-line treatment for locally advanced or metastatic urothelial carcinoma: the progression from platinum-based chemotherapy to platinum-free therapy","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/gt.2014.122","article-title":"Potent antitumor activity of Oct4 and hypoxia dual-regulated oncolytic adenovirus against bladder cancer","volume":"22","author":"Lu","year":"2015","journal-title":"Gene Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"15622","DOI":"10.3390\/ijms232415622","article-title":"Therapeutic applications for oncolytic self-replicating RNA viruses","volume":"23","author":"Lundstrom","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/bjc.1995.160","article-title":"Retinoblastoma gene mutations in primary human bladder cancer","volume":"71","author":"Miyamoto","year":"1995","journal-title":"Br. J. Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12032-025-02735-z","article-title":"CAR T-cell therapy in renal cell carcinoma: opportunities, challenges, and new strategies to overcome","volume":"42","author":"Mohammadi","year":"2025","journal-title":"Med. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"10363","DOI":"10.1002\/cam4.5767","article-title":"Clinical application of the anti-human telomerase reverse transcriptase (hTERT) antibody (SCD-A7) immunocytochemistry in liquid-based urine cytology: a prospective, single institute study","volume":"12","author":"Moon","year":"2023","journal-title":"Cancer Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J. Urol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.urolonc.2021.01.022","article-title":"hTERT, hTR and TERT promoter mutations as markers for urological cancers detection: a systematic review","volume":"498","author":"Morozov","year":"2021","journal-title":"Urol. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3390\/v15081645","article-title":"Oncolytic virus engineering and utilizations: cancer immunotherapy perspective","volume":"15","author":"Muthukutty","year":"2023","journal-title":"Viruses"},{"key":"B65","first-page":"2985","article-title":"Fiber-substituted conditionally replicating adenovirus for oncolysis of human renal carcinoma cells","volume":"32","author":"Nagaya","year":"2012","journal-title":"Anticancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with Bacillus Calmette-Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J. Urol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.eururo.2017.05.033","article-title":"Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling","volume":"73","author":"Pal","year":"2018","journal-title":"Eur. Urol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"key":"B70","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/mt.2008.307","article-title":"Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver","volume":"17","author":"Paolo","year":"2009","journal-title":"Mol. Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1158\/0008-5472.CAN-22-1444","article-title":"KDM6A loss triggers an epigenetic switch that disrupts urothelial differentiation and drives cell proliferation in bladder cancer","volume":"83","author":"Qiu","year":"2023","journal-title":"Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Ramesh","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.3390\/cancers15194886","article-title":"Current and emerging strategies to treat urothelial carcinoma","volume":"15","author":"Rani","year":"2023","journal-title":"Cancers"},{"key":"B74","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"B75","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3233\/KCA-190058","article-title":"A review of papillary renal cell carcinoma and MET inhibitors","volume":"3","author":"Rhoades Smith","year":"2019","journal-title":"Kidney Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.18632\/oncotarget.2151","article-title":"Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter","volume":"5","author":"Seo","year":"2014","journal-title":"Oncotarget"},{"key":"B78","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10637-021-01073-x","article-title":"Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer models","volume":"39","author":"Shang","year":"2021","journal-title":"Invest. New Drugs"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/mt.2009.217","article-title":"Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus","volume":"17","author":"Shashkova","year":"2009","journal-title":"Mol. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-022-01352-x","article-title":"Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8(+) T cell cytolytic killing of melanoma cells","volume":"15","author":"Shaw","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e14574","DOI":"10.1200\/JCO.2024.42.16_suppl.e14574","article-title":"A novel co-receptor with mutated TIGIT to enhance PSCA CAR-T therapy for bladder cancer","volume":"42","author":"Shen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.hoc.2023.04.011","article-title":"von-Hippel Lindau and Hypoxia-Inducible factor at the center of renal cell carcinoma biology","volume":"37","author":"Shirole","year":"2023","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1158\/1535-7163.MCT-10-0332","article-title":"Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy","volume":"9","author":"Short","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/iju.13325","article-title":"Current status of clinical trials assessing oncolytic virus therapy for urological cancers","volume":"24","author":"Taguchi","year":"2017","journal-title":"Int. J. Urol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2147\/OTT.S41978","article-title":"Human telomerase reverse-transcriptase promoter-controlled and herpes simplex virus thymidine kinase-armed adenoviruses for renal cell carcinoma treatment","volume":"6","author":"Tian","year":"2013","journal-title":"Onco. Targets. Ther."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/01.JU.0001015816.87470.c9.02","article-title":"P2-02 pivotal results from BOND-003: a phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ","volume":"211","author":"Tyson","year":"2024","journal-title":"J. Urol."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS598","article-title":"A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)","author":"Uchio","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41417-025-00879-8","article-title":"A conditionally replicative adenovirus vector containing the synNotch receptor gene for the treatment of muscle-invasive bladder cancer","volume":"32","author":"Ueki","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0022-5347(05)64905-1","article-title":"Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer","volume":"168","author":"van der Poel","year":"2002","journal-title":"J. Urol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","article-title":"FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma","volume":"64","author":"van Rhijn","year":"2004","journal-title":"Cancer Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Futreal, Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1016\/j.ymthe.2025.07.034","article-title":"Oncolytic HSV and cancer drug interactions: current clinical status and future directions","volume":"33","author":"V\u00e1zquez-Arregu\u00edn","year":"2025","journal-title":"Mol. Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.urology.2013.10.025","article-title":"Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F\/RGD on bladder cancer","volume":"508","author":"Wang","year":"","journal-title":"Urology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.urology.2006.04.021","article-title":"Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model","volume":"68","author":"Wang","year":"2006","journal-title":"Urology"},{"key":"B98","doi-asserted-by":"publisher","first-page":"10879","DOI":"10.1007\/s13277-014-2353-7","article-title":"Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro","volume":"35","author":"Wang","year":"","journal-title":"Tumour Biol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s12672-025-02772-0","article-title":"Trends and hotspots in targeted therapy resistance research for renal cell carcinoma: a bibliometric and visualization analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Discov. Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1158\/1078-0432.CCR-07-1047","article-title":"Tumor-selective replication of an oncolytic adenovirus carrying oct-3\/4 response elements in murine metastatic bladder cancer models","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1133832","DOI":"10.3389\/fonc.2023.1133832","article-title":"Treatment strategies for clear cell renal cell carcinoma: past, present and future","volume":"13","author":"Yang","year":"2023","journal-title":"Front. Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e1760","DOI":"10.1038\/cddis.2015.128","article-title":"RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1089\/hum.2019.059","article-title":"An oncolytic adenovirus targeting transforming growth factor \u03b2 inhibits protumorigenic signals and produces immune activation: a novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy","volume":"30","author":"Yang","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1360436","DOI":"10.3389\/fimmu.2024.1360436","article-title":"Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3\u03b2 inhibitor enhances antitumor immune response against bladder cancer","volume":"15","author":"Yoon","year":"2024","journal-title":"Front. Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2174\/156800907780058817","article-title":"Clinical trials with oncolytic adenovirus in China","volume":"7","author":"Yu","year":"2007","journal-title":"Curr. Cancer Drug Targets"},{"key":"B106","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jcb.22328","article-title":"The influence of innate and pre-existing immunity on adenovirus therapy","volume":"108","author":"Zaiss","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/gt.2011.180","article-title":"Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer","volume":"19","author":"Zhai","year":"2012","journal-title":"Gene Ther."},{"key":"B108","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.omto.2021.11.018","article-title":"Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma","volume":"24","author":"Zhang","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"B109","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41419-024-06734-2","article-title":"Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors","volume":"15","author":"Zhang","year":"","journal-title":"Cell Death Dis."},{"key":"B110","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/09553002.2017.1231942","article-title":"Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells","volume":"93","author":"Zhang","year":"2017","journal-title":"Int. J. Radiat. Biol."},{"key":"B111","first-page":"3743","article-title":"Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel","volume":"62","author":"Zhang","year":"2002","journal-title":"Cancer Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/hum.2019.352","article-title":"Efficacy of an oncolytic adenovirus driven by a chimeric promoter and armed with decorin against renal cell carcinoma","volume":"31","author":"Zhang","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"B113","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1186\/s12951-024-02903-9","article-title":"Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment","volume":"22","author":"Zhang","year":"","journal-title":"J. Nanobiotechnol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fimmu.2018.00335","article-title":"Seroprevalence of neutralizing antibodies against human adenovirus type-5 and chimpanzee adenovirus type-68 in cancer patients","volume":"9","author":"Zhao","year":"2018","journal-title":"Front. Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/cgt.2008.61","article-title":"Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA","volume":"16","author":"Zheng","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2200094","DOI":"10.1002\/gch2.202200094","article-title":"Combining of oncolytic virotherapy and other immunotherapeutic approaches in cancer: a powerful functionalization tactic","volume":"7","author":"Zou","year":"2023","journal-title":"Glob. Chall."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1729087\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T05:13:21Z","timestamp":1765257201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1729087\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":116,"alternative-id":["10.3389\/fmicb.2025.1729087"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1729087","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"article-number":"1729087"}}